News Releases

News Releases

Nov 12, 2019

Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced financial results for the third
Nov 05, 2019

Merus Announces Pricing of Public Offering of Common Shares

UTRECHT, The Netherlands , and CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of
Nov 04, 2019

Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics ® , today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares.
Oct 27, 2019

Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Of nine patients enrolled across the MCLA-128 Early Access Program
Oct 25, 2019

Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Company to host investor call on Monday, October 28th at 8:00AM ET UTRECHT, The Netherlands and BOSTON , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing Biclonics®, innovative full-length
Aug 19, 2019

Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the
Jun 03, 2019

Merus to Present at the Jefferies 2019 Healthcare Conference

UTRECHT, Netherlands , June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
May 30, 2019

Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update

UTRECHT, The Netherlands , May 30, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced financial results for the
May 23, 2019

Merus Announces 2019 Annual General Meeting of Shareholders

UTRECHT, The Netherlands , May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General
May 20, 2019

Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

UTRECHT, Netherlands , May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
May 09, 2019

Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

UTRECHT, Netherlands , May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating
Apr 03, 2019

Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

Multiple Updates from Biclonics® Clinical Trials Expected in 2019 UTRECHT, The Netherlands , April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics ® , innovative full-length human
Apr 01, 2019

Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

CD137 and PD-L1 bispecific antibody with context-dependent T cell activation UTRECHT, Netherlands , April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human
Mar 11, 2019

Merus to Present at the Cowen & Co. 39th Annual Health Care Conference

UTRECHT, Netherlands , March 11, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D.,
Feb 07, 2019

Merus to Participate in Guggenheim Healthcare Talks Idea Forum

UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Scientific
Jan 07, 2019

Merus Announces IND Clearance for MCLA-145

MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today
Jan 02, 2019

Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing